Lestaurtinib is an orally bioavailable indolocarbazole alkaloid that functions as a potent JAK2 inhibitor, belonging to the kinase inhibitor class of therapeutic agents. During clinical development, this… Read more
Lestaurtinib is an orally bioavailable indolocarbazole alkaloid that functions as a potent JAK2 inhibitor, belonging to the kinase inhibitor class of therapeutic agents. During clinical development, this compound has been investigated for the treatment of various malignancies, including pancreatic and prostate cancers, refractory neuroblastoma, and myeloproliferative disorders such as V617F JAK2-positive polycythemia vera and essential thrombocytosis. Pharmaceutical laboratories require high-quality Lestaurtinib reference standards and related impurities, such as N-nitroso Lestaurtinib, to ensure rigorous quality control and precise impurity profiling. These analytical tools are essential for characterizing the active pharmaceutical ingredient, monitoring degradation pathways, and validating bioanalytical methods. By utilizing stable isotope labelled compounds and precise impurity references, researchers can maintain compliance with regulatory standards throughout drug development, ensuring the reliability of data used in safety and efficacy assessments for these complex therapeutic candidates.